Specific sublingual immunotherapy in atopic dermatitis. Results of a 6-year follow-up of 35 consecutive patients

Allergologia et Immunopathologia

Volumn 28, Issue 2, 2000, Pages 54-62

  Mastrandrea, F ^a   Serio, G ^b   Minelli, M ^c   Minardi, A ^a   Scarcia, G ^a   Coradduzza, G ^a   Parmiani, Silvano ^d  

^a Allerg and Clin Immunol Oper U   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF SALENTO   (Italy)

^d ALK Abello SpA   (Italy)

Author keywords

Allergens; Atopic dermatitis; Effectiveness; Safety; Sublingual specific immunotherapy

Indexed keywords

IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; BLOOD; CHILD; CLINICAL TRIAL; DESENSITIZATION; FEMALE; HUMAN; MALE; PRESCHOOL CHILD; RETROSPECTIVE STUDY; SKIN TEST; SUBLINGUAL DRUG ADMINISTRATION;

ADMINISTRATION, SUBLINGUAL; ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DERMATITIS, ATOPIC; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; MALE; RETROSPECTIVE STUDIES; SKIN TESTS;

EID: 0034150956     PISSN: 03010546     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92:44-7.
2. Leung DYM. Atopic Dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol 1995;96:302-19.
3. Schultz-Larsen F, Holm K, Henningsen K. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1986;15:487-94.
4. Hanifin JM, Butler JM, Chan SC. Immunopharmacology of the atopic diseases. J Invest Dermatol 1985;85:161-4.
5. Saurat JH. Eczema in primary immune-deficiencies: clues to the pathogenesis of atopic dermatitis with special reference to the Wiskott-Aldrich syndrome. Acta Derm Venereol 1985;114:125-8.
6. Mastrandrea F, Minardi A, Coradduzza G, Rossi N, Cadario G. Atopic dermatitis: towards a plausible pathogenetic model. Giornale Ital Allergol Immunol Clin 1998;8:503-17.
7. Leung DYM, Hirsch RL, Schneider L, Moody C, Takaoka R, Li SH, et al. Thymopentin therapy reduces the clinical severity of atopic dermatitis J Allergy Clin Immunol 1990;85:927-33.
8. Boguniewicz M, Jaffe HS, Izu A. Recombinant gamma Interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88:365-70.
9. Sowden JM, Berth-Jones J, Ross JS. Double-blind, controlled, cross-over study of cyclosporin in adults with severe refractory atopic dermatitis. Lancet 1991;1338:137-40.
10. Ruzicka T, Bieber T, Schopf E. A short term trial of tacrolimus ointment for atopic dermatitis. New Engl J Med 1997;337: 816.
11. Bousquet J, Lockey RF, Mailing HJ. WHO Position Paper. Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. Allergy 1998;53 Supl 44.
12. Glover MT, Atherton DJ. A double-blind controlled trial of hyposensitization to Dermatophagoides pteronyssinus in children with atopic eczema. Clin Exp Allergy 1992;22:440-6.
13. Leroy B, Lachapelle JM, Jacquemin MG, Saint-Remy IM. Immunotherapy of atopic dermatitis by injection of antigen-antibody complexes. Dermatology 1993;186:276-7.
14. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereol 1980;92 Supl:44-7.
15. Stalder JF, Taieb A, Atherton DJ. Severity scoring of atopic dermatitis: The SCORAD Index. Dermatology 1993;186:23-31.
16. Carreira J, Lombardero M, Ventas P. New developments in in vitro methods. Quantification of clinically relevant allergens in mass units. In: Arbeiten aus dem Paul Ehrlich Institut. Stuttgart: Gustav Fischer Verlag; 1994.
17. Chapman MD, Rowntree S, Mitchell EB. Quantitative assessment of IgG and IgE antibodies to inhalant allergens in patients with atopic dermatitis. J Allergy Clin Immunol 1983;72:27-33.
18. Roberts DLL. House dust mite avoidance and atopic dermatitis. Br J Dermatol 1984;110:735-9.
19. Gondo A, Saeki N, Tokuda Y. Challenge reactions in atopic dermatitis after percutaneous entry of mite antigen. Br J Dermatol 1986;115:485-93.
20. Norris PG, Schofield O, Camp RDR. A study of the role of house dust mite in atopic dermatitis. Br J Dermatol 1988;118: 435-40.
21. Adinoff AD, Tellez P, Clark RAF. Atopic dermatitis and aeroallergens contact sensitivity. J Allergy Clin Immunol 1988;81: 736-42.
22. Tupker RA, de Monchy JGR, Coenraads PJ, Homan A, van der Meer JB. Induction of atopic dermatitis by inhalation of house dust mite. J Allergy Clin Immunol 1996;97:1064-70.
23. Bock SA, Lee WY, Remigio LK, May CD. Studies of hyper-sensitivity reactions to foods in infants and children. J Allergy Clin Immunol 1978;62:327-34.
24. Jones SM, Sampson HA. The role of allergens in atopic dermatitis. Clin Rev Allergy 1993;11:471-90.
25. Jones HE, Reinhardt JH, Rinaldi MG. A clinical, mycological and immunological survey for dermatophytosis. Arch Dermatol 1973;107:217-22.
26. Kieffer M, Bergbrant I-M, Faegermann J. Immune reactions to Pytirosporum in adult patients with atopic and seborrheic dermatitis. J Am Acad Dermatol 1990;22:739-42.
27. Leyden JE, Marples RR, Kligman AM. Staphylococcus aureus in the lesions of atopic dermatitis. Br J Dermatol 1990; 90:525-30.
28. Leung DYM, Harbeck R, Bina P. Presence of IgE antibodies to staphylococcal exotoxin on the skin of patients with atopic dermatitis: evidence for a new group of allergens. J Clin Invest 1993;92:1374-80.
29. Werfel T, Kapp A. Environmental and other major provocation factors in atopic dermatitis. Allergy 1998;53:731-900.
30. Mosca M, Albani-Rocchetti G, Vignini MA, Ubezio S, Nume AG, Di Silverio A. La vaccinoterapia sublinguale nella dermatite atopica. G Ital Dermatol Venereol 1993;128:79-83.
31. Moses LE. Le serie di casi consecutivi come strumento per valutare gli esiti degli Interventi medici. In: Bailar III JC, Mosteller F (eds.). L'uso della statistica in medicina. Roma: II Pensiero Scientifico Editore; 1988. p. 97-110.
32. Mailing HJ, Weeke B. EAACI Position Paper: Immunotherapy. Allergy 1993;48 Supl 14:9-35.
33. Tari MG, Mancino M, Monti G. Efficacy of sublingual imunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol et Immunopathol 1990;18:277-84.
34. Sabbah A, Hassoun S, Le Sellin J, Andrè C, Sicard H. A double-blind placebo controlled trial by the sublingual route of immunotherapy with a standardised grass pollen extract. Allergy 1994;49:309-13.
35. Troise C, Voltolini S, Canessa A, Pecora S, Negrini AC. Sublingual immunotherapy in Parietaria pollen induced rhinitis: a double blind study. J Invest Allergol Clin Immunol 1995;5:25-30.
36. Feliziani V, Lattuada G, Parmiani S, Dall'Aglio PP. Safety and efficacy of sublingual rush immunotherapy with grass allergen extracts. A double blind study. Allergol et Immunopathol 1995;23:224-30.
37. Quirino T, lemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy 1996;26:1253-61.
38. Purello D'Ambrosio F, Ricciardi L, Isola S. Rush sublingual immunotherapy in Parietaria-allergic patients. Allergol et Immunopathol 1996;21:146-51.
39. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite (D. pt) in children. Pediatr Allergy Immunol 1997;8:21-7.
40. Bousquet J, Scheinmann P, Guinnepain MT. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249-60.
41. Purello D'Ambrosio F, Gangemi S, Isola S, La Motta N, Puccinelli P, Parmiani S, et al. Sublingual immunotherapy: a double-blind, placebo-controlled trial with Parietaria judaica extract standardised in mass units in patients with rhinoconjunctivitis, asthma, or both. Allergy 1999;54:968-73.
42. Mailing HJ. Sublingual immunotherapy. Clin Exp Allergy 1996; 26:1228-31.
43. Bergmann RL, Edenharter G, Bergmann KE. Atopic dermatitis in early infancy predicts allergic airway disease at 5 years. Clin Exp Allergy 1998;28:965-70.
44. Iikura Y, Naspitz CK, Mikawa. Prevention of asthma by ketotifen in infants with atopic dermatitis. Ann Allergy 1992;68: 233-6.
45. Mosbech H, Osterballe O. Does the effect of immunotherapy last after termination of the treatment? Follow-up study in patients with grass pollen rhinitis. Allergy 1988;43:523-9.
46. Jacobsen L, Nuchel Petersen B, Wihl JA, Lowenstein H, Ipsen H. Immunotherapy with partially purified and standardised tree pollen extracts. IV Results from long-term (6.year) follow-up. Allergy 1997;52:914-20.
47. Price JF, Warner JO, Hey EN, Turner MW, Soothill JF. A controlled trial of hyposensitisation with adsorbed tyrosine Dermatophagoides pteronyssinus antigen in childhood asthma. Clin Exp Allergy 1984;14:209-19.
48. Grammer LC, Shaughnessy MA, Suszko IM. Persistence of efficacy after a brief course of polymerized ragweed allergen: a controlled study. J Allergy Clin Immunol 1984;73:484-9.
49. Des Roches A, Paradis L, Knani J. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. V. Duration of efficacy of immunotherapy after its cessation. Allergy 1996;51:430-3.
50. Des Roches A, Paradis L, Menardo JL, Bouges S, Daures JO, Bousquet J. Immunotherapy with a standardised Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitisations in children. J Allergy Clin Immunol 1997;99:450-3.
51. Secrist H, Chelen CJ, Wen Y, Marshall JD, Umetsu DT. Allergen immunotherapy decreases interleukin 4 production in CD4+ T cell from allergic individuals. J Exp Med 1993;178: 2123-30.
52. Ebner C, Siemann U, Bohle B. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy 1997;27:1007-15.
53. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J Allergy Clin Immunol 1998;102: 157-64.
54. Fasler S, Aversa G, Terr A. Peptide-induced anergy in allergen-specific human TH2 cells results in lack of cytokine production and B cell help for IgE synthesis. Reversal by IL-2, not by IL-4 or IL-13. J Immunol 1995;155:4199-206.
55. Akdis CA, Akdis M, Blesken T. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest 1996;98:1676-83.
56. Bernstein JA, Munson J, Lummus ZL, Balakrishnan K, Leikauf G. T-cell receptor V-beta gene segment expression in diisocyanate-induced occupational asthma. J Allergy Clin Immunol 1997;99:245-50.
57. Bagnasco M, Mariani M, Passalacqua G. Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beings. J Allergy Clin Immunol 1997;100:122-9.
58. Mastrandrea F. The specific immunotherapy action on the allergic cellular infiltrates: TH2/TH1 switching versus a negative selection during a neo-ontogeny. Advanced Seminar in Allergy and Clinical Immunology 1999;28-29 May, Taranto, Italy.
59. Denburg JA, Inman MD, Leber B, Sehmi R, O'Byrne PM. The role of the bone marrow in allergy and asthma. Allergy 1996; 51:141-8.
60. Denburg JA. Hemopoietic progenitors and cytokines in allergic inflammation. Allergy 1998;53:22-6.
61. Kim YK, Uno M, Hamilos DL, Beck L, Bochner B, Schleimer R, et al. Immunolocalisation of CD34 in nasal polyposis. Am J Resp Cell Mol Biol 1999;20:388-97.
62. Mastrandrea F, Cadario G, Bedello PG, Nicotra MR, Natali PG. Expression of T-lineage early developmental markers by cells establishing atopic dermatitis skin infiltrates. J Invest Allergol Clin Immunol 1998;8:359-64.
63. Mastrandrea F, Cadario G, Nicotra MR, Natali PG. Hemopoietic progenitor cells in atopic dermatitis skin lesions. J Invest Allergol Clin Immunol 1999 (in press).
64. Durham SR, Walker SM, Varga EM. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341: 468-75.